These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

962 related articles for article (PubMed ID: 33950278)

  • 21. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
    Park SJ; Yu KM; Kim YI; Kim SM; Kim EH; Kim SG; Kim EJ; Casel MAB; Rollon R; Jang SG; Lee MH; Chang JH; Song MS; Jeong HW; Choi Y; Chen W; Shin WJ; Jung JU; Choi YK
    mBio; 2020 May; 11(3):. PubMed ID: 32444382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial.
    Aricò E; Castiello L; Bracci L; Urbani F; Lombardo F; Bacigalupo I; Ancidoni A; Vanacore N; Falcione A; Reggiani C; Dutti GM; Maglie MG; Papa O; Bartoletti PL; Ozzella G; Bevilacqua N; Nicastri E; Belardelli F; Sconocchia G
    Trials; 2021 Sep; 22(1):584. PubMed ID: 34479601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin-Converting Enzyme 2 Potentiates SARS-CoV-2 Infection by Antagonizing Type I Interferon Induction and Its Down-Stream Signaling Pathway.
    Chen J; Liu J; Chen Z; Peng H; Zhu C; Feng D; Zhang S; Zhao P; Zhang X; Xu J
    mSphere; 2022 Aug; 7(4):e0021122. PubMed ID: 35862802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.
    Ramasamy S; Subbian S
    Clin Microbiol Rev; 2021 Jun; 34(3):. PubMed ID: 33980688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Type I IFNs: A Blessing in Disguise or Partner in Crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-Induced Pathology and Potential Use of Type I IFNs in Synergism with IFN-
    Anjum FR; Anam S; Abbas G; Mahmood MS; Rahman SU; Goraya MU; Abdullah RM; Luqman M; Ali A; Akram MK; Chaudhry TH
    Viral Immunol; 2021 Jun; 34(5):321-329. PubMed ID: 33181057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interplay between SARS-CoV-2 and the type I interferon response.
    Sa Ribero M; Jouvenet N; Dreux M; Nisole S
    PLoS Pathog; 2020 Jul; 16(7):e1008737. PubMed ID: 32726355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antagonism of Type I Interferon by Severe Acute Respiratory Syndrome Coronavirus 2.
    Xia H; Shi PY
    J Interferon Cytokine Res; 2020 Dec; 40(12):543-548. PubMed ID: 33337934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: Implications for treatment with IFN-β and IFN inducer.
    Shuai H; Chu H; Hou Y; Yang D; Wang Y; Hu B; Huang X; Zhang X; Chai Y; Cai JP; Chan JF; Yuen KY
    J Infect; 2020 Oct; 81(4):e1-e10. PubMed ID: 32707230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
    Shah VK; Firmal P; Alam A; Ganguly D; Chattopadhyay S
    Front Immunol; 2020; 11():1949. PubMed ID: 32849654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID-19 mRNA vaccine protects against SARS-CoV-2 Omicron BA.1 infection in diet-induced obese mice through boosting host innate antiviral responses.
    Chen Y; Song W; Li C; Wang J; Liu F; Ye Z; Ren P; Tong Y; Li J; Ou Z; Lee AC; Cai JP; Wong BH; Chan JF; Yuen KY; Zhang AJ; Chu H
    EBioMedicine; 2023 Mar; 89():104485. PubMed ID: 36857860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system.
    Zhu Q; Zhang Y; Wang L; Yao X; Wu D; Cheng J; Pan X; Liu H; Yan Z; Gao L
    Antiviral Res; 2021 Mar; 187():105015. PubMed ID: 33444702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 Isolates Show Impaired Replication in Human Immune Cells but Differential Ability to Replicate and Induce Innate Immunity in Lung Epithelial Cells.
    Jiang M; Kolehmainen P; Kakkola L; Maljanen S; Melén K; Smura T; Julkunen I; Österlund P
    Microbiol Spectr; 2021 Sep; 9(1):e0077421. PubMed ID: 34378952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiviral activities of type I interferons to SARS-CoV-2 infection.
    Mantlo E; Bukreyeva N; Maruyama J; Paessler S; Huang C
    Antiviral Res; 2020 Jul; 179():104811. PubMed ID: 32360182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Roles of Type I and III Interferons in COVID-19.
    Choi H; Shin EC
    Yonsei Med J; 2021 May; 62(5):381-390. PubMed ID: 33908208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model.
    Dhakal S; Ruiz-Bedoya CA; Zhou R; Creisher PS; Villano JS; Littlefield K; Ruelas Castillo J; Marinho P; Jedlicka AE; Ordonez AA; Bahr M; Majewska N; Betenbaugh MJ; Flavahan K; Mueller ARL; Looney MM; Quijada D; Mota F; Beck SE; Brockhurst J; Braxton AM; Castell N; Stover M; D'Alessio FR; Metcalf Pate KA; Karakousis PC; Mankowski JL; Pekosz A; Jain SK; Klein SL;
    mBio; 2021 Aug; 12(4):e0097421. PubMed ID: 34253053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between Type I Interferon Associated Factors and COVID-19 Severity.
    Bencze D; Fekete T; Pázmándi K
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral response and immunopathogenesis of interleukin 27 in COVID-19.
    Valdés-López JF; Urcuqui-Inchima S
    Arch Virol; 2023 Jun; 168(7):178. PubMed ID: 37310504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience.
    Pereda R; González D; Rivero HB; Rivero JC; Pérez A; López LDR; Mezquia N; Venegas R; Betancourt JR; Domínguez RE
    J Interferon Cytokine Res; 2020 Sep; 40(9):438-442. PubMed ID: 32960147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.